# A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

> **NCT00686075** · PHASE1,PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 1338 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** MEDI-534, Cohort 1
- **OTHER:** Placebo, Cohort 1
- **BIOLOGICAL:** MEDI-534, Cohort 2
- **OTHER:** Placebo, Cohort 2
- **BIOLOGICAL:** MEDI-534, Cohort 3
- **OTHER:** Placebo, Cohort 3
- **BIOLOGICAL:** MEDI-534, Cohort 4
- **OTHER:** Placebo, Cohort 4
- **BIOLOGICAL:** MEDI-534, Cohort 5
- **OTHER:** Placebo, Cohort 5

## Key facts

- **NCT ID:** NCT00686075
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 1338 (ACTUAL)
- **Last updated:** 2014-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00686075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00686075, "A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT00686075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*